Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Gov't to Relax Belt-Tightening Fiscal Policy
December 15, 2008
- REGULATORY NEWS IN BRIEF
December 15, 2008
- VITAL KSK Holdings Aims at Sales of \600 Bil. in FY2012
December 8, 2008
- JACDS Objects to JODA's Voluntary GLs
December 8, 2008
- Price Negotiations Make Little Headway at Major Hospitals
December 8, 2008
- DPJ's Council Favors Restrictions of Online Sales of Drugs
December 8, 2008
- Yakult Honsha: Strong Sales of Elplat Prop Up Pharma Business
December 8, 2008
- Creams for Vaginal Candidiasis Recommended for Approval as Switch OTC Drugs
December 8, 2008
- TOP QUARK to Provide Int'l Clinical Development Project Management Services
December 8, 2008
- SELF-MEDICATION NEWS IN BRIEF
December 8, 2008
- Licensing Negotiations Underway for Drug for MS: MediciNova
December 8, 2008
- Annual Breast Cancer Examination Recommended for Patients on HRT
December 8, 2008
- BUSINESS NEWS IN BRIEF
December 8, 2008
- Children with SGA Short Stature Require Early Treatment: Pfizer Seminar
December 8, 2008
- MOF Proposes Carrot-and-Stick Approach to Encourage Insurers to Use More Generics
December 8, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
December 8, 2008
- Share of Generics Too Low: MOF Council
December 8, 2008
- 2 Drugs for CML, 2 Anti-HIV Drugs Recommended for Approval
December 8, 2008
- REGULATORY NEWS IN BRIEF
December 8, 2008
- NBI Opens Research Institute in Kobe
December 8, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…